Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Current Liabilities: 2014-2024

Historic Total Current Liabilities for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $54.9 million.

  • ImmunityBio's Total Current Liabilities fell 6.28% to $57.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.1 million, marking a year-over-year decrease of 6.28%. This contributed to the annual value of $54.9 million for FY2024, which is 5.73% down from last year.
  • According to the latest figures from FY2024, ImmunityBio's Total Current Liabilities is $54.9 million, which was down 5.73% from $58.3 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Total Current Liabilities peaked at $500.9 million during FY2022, and registered a low of $54.9 million during FY2024.
  • Its 3-year average for Total Current Liabilities is $204.7 million, with a median of $58.3 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 489.45% in 2020, then crashed by 88.36% in 2023.
  • Yearly analysis of 5 years shows ImmunityBio's Total Current Liabilities stood at $68.1 million in 2020, then spiked by 441.57% to $369.0 million in 2021, then spiked by 35.74% to $500.9 million in 2022, then tumbled by 88.36% to $58.3 million in 2023, then declined by 5.73% to $54.9 million in 2024.